Read by QxMD icon Read

subcutaneous defibrilator review

Angelo Auricchio, J Harrison Hudnall, Edward J Schloss, Laurence D Sterns, Takashi Kurita, Albert Meijer, Dedra H Fagan, Tyson Rogers
Aims: Single-chamber (VR-ICD) and subcutaneous (S-ICD) implantable cardioverter-defibrillators are effective to protect patients against sudden death but expose them to higher risk of inappropriate shock (IS). We sought to quantify the annual rate and influencing factors of ISs in VR- and S-ICDs from the literature. Methods and results: PubMed, Embase, and Cochrane Library were searched for full text articles with IS rates. Poisson distribution estimated proportion of patients with ISs; rates were annualized based on follow-up duration...
March 10, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
Christopher J McLeod, Lucas Boersma, Hideo Okamura, Paul A Friedman
No abstract text is available yet for this article.
January 21, 2017: European Heart Journal
Skevos Sideris, Stefanos Archontakis, Konstantinos A Gatzoulis, Aristotelis Anastasakis, Ilias Sotiropoulos, Petros Arsenos, Alexandros Kasiakogias, Dimitrios Terentes, Konstantinos Trachanas, Eleftherios Paschalidis, Dimitrios Tousoulis, Ioannis Kallikazaros
The introduction of the implantable cardioverter defibrillator (ICD) in clinical practice has revolutionized our therapeutic approach for sudden cardiac death (SCD) both in the context of primary and secondary prevention, since it has proven to be superior to medical therapy in treating potentially life-threatening ventricular arrhythmias, resulting in reduced mortality rates. However, conventional ICDs' implantation carries a not negligible risk of periprocedural and long-term complications associated with the transvenous ICD leads...
February 2, 2017: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
Matthew Bennett, Ratika Parkash, Pablo Nery, Mario Sénéchal, Blandine Mondesert, David Birnie, Laurence D Sterns, Claus Rinne, Derek Exner, François Philippon, Debra Campbell, Jafna Cox, Paul Dorian, Vidal Essebag, Andrew Krahn, Jaimie Manlucu, Franck Molin, Michael Slawnych, Mario Talajic
Sudden cardiac death is a major public health issue in Canada. However, despite the overwhelming evidence to support the use of implantable cardioverter defibrillators (ICDs) in the prevention of cardiac death there remains significant variability in implantation rates across Canada. Since the most recent Canadian Cardiovascular Society position statement on ICD use in Canada in 2005, there has been a plethora of new scientific information to assist physicians in their discussions with patients considered for ICD implantation to prevent sudden cardiac death due to ventricular arrhythmias...
February 2017: Canadian Journal of Cardiology
Jason Huang, Kristen K Patton, Jordan M Prutkin
BACKGROUND: The subcutaneous implantable cardioverter defibrillator (S-ICD) is a novel implanted defibrillator for the prevention of sudden cardiac death that avoids intravascular access. Use of this device is limited by its inability to provide backup pacing. Combined use of the S-ICD with a permanent pacemaker may be the optimal choice in certain situations though experience with the use of both devices together remains limited. METHODS: We reviewed our single-center experience with the S-ICD from March 2011 to November 2015...
November 2016: Pacing and Clinical Electrophysiology: PACE
Yusuke Kondo, Marehiko Ueda, Yoshio Kobayashi, Joerg O Schwab
There has been a significant increase in the number of patients receiving cardiovascular implantable electronic devices (CIED) over the last two decades. CIED infection represents a serious complication after CIED implantation and is associated with significant morbidity and mortality. Recently, newly advanced technologies have offered attractive and suitable therapeutic alternatives. Notably, the leadless pacemaker and anti-bacterial envelope decrease the potential risk of CIED infection and the resulting mortality, when it does occur...
August 2016: Journal of Arrhythmia
Mark E Willcox, Jordan M Prutkin, Gust H Bardy
The subcutaneous implantable cardioverter-defibrillator (ICD) was developed as a simple device to reduce the morbidity of ICD therapy while providing a comparable reduction in sudden death from ventricular fibrillation. This review highlights the differences compared to the traditional ICD. It includes recent data on safety and efficacy, as well as best practices on screening and programming, and discusses expected future developments.
August 2016: Trends in Cardiovascular Medicine
Jo Jo Hai, Eric Tien-Siang Lim, Chin-Pang Chan, Yat-Sun Chan, Kwok-Keung Chan, Daniel Chong, Kah-Leng Ho, Boon-Yew Tan, Wee-Siong Teo, Chi-Keong Ching, Hung-Fat Tse
AIMS: The safety and feasibility of a subcutaneous implantable cardioverter-defibrillator (S-ICD) has been demonstrated in the treatment of life-threatening ventricular tachyarrhythmias (VT). Nonetheless, its safety and feasibility in an Asian population with smaller body-build is unclear. METHODS AND RESULTS: Twenty-one Asian patients who underwent S-ICD from 1 April 2014 to 2 February 2015 in five institutions in Hong Kong and Singapore were retrospectively reviewed...
October 2015: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
Hussam Ali, Pierpaolo Lupo, Riccardo Cappato
Although conventional implantable cardioverter-defibrillators (ICDs) have proved effective in the prevention of sudden cardiac death (SCD), they still appear to be limited by non-trivial acute and long-term complications. The recent advent of an entirely subcutaneous ICD (S-ICD) represents a further step in the evolution of defibrillation technology towards a less-invasive approach. This review highlights some historical and current issues concerning the S-ICD that may offer a viable therapeutic option in selected patients at high risk of SCD and in whom pacing is not required...
August 2015: Arrhythmia & Electrophysiology Review
Daniel Mangels, William H Frishman
The subcutaneous implantable cardioverter defibrillator (S-ICD) is a subcutaneous alternative to conventional transvenous ICD (TV-ICD) systems, which have previously been shown to treat life-threatening ventricular tachyarrhythmias in cardiac disease patients. A review of the literature reveals that S-ICDs have similar shock efficacy rates for both induced and spontaneous ventricular tachyarrhythmias when compared with TV-ICDs. Furthermore, S-ICDs seem to have a higher specificity for withholding therapy when supraventricular tachycardia is present compared with TV-ICDs...
September 2016: Cardiology in Review
Christopher J McLeod, Lucas Boersma, Hideo Okamura, Paul A Friedman
The subcutaneous implantable cardioverter defibrillator (ICD) provides therapy for the prevention of sudden cardiac death while avoiding the numerous complications associated with transvenous leads. This relatively novel device employs an innovative approach to sensing and defibrillation from outside of the thoracic cage. Substantial data from cohort studies and registries have accrued and can be used to inform patient eligibility, implant technique, and efficacy compared with the standard transvenous ICD. This review serves to update the clinician as to current evidence and the nuances involved in the optimal utilization of this innovative technology...
October 29, 2015: European Heart Journal
Tien Siang Eric Lim, Boon Yew Tan, Kah Leng Ho, Chuh Yih Paul Lim, Wee Siong Teo, Chi-Keong Ching
Transvenous implantable cardioverter defibrillators are a type of implantable cardiac device. They are effective at reducing total and arrhythmic mortality in patients at risk of sudden cardiac death. Subcutaneous implantable cardioverter defibrillators (S-ICDs) are a new alternative that avoids the disadvantages of transvenous lead placement. In this case series, we report on the initial feasibility and safety of S-ICD implantation in Singapore.
October 2015: Singapore Medical Journal
Juan F Iglesias, Pierre Monney, Patrizio Pascale, Patrick Yerly, Olivier Muller, Juerg Schwitter, Roger Hullin, Eric Eeckhout, Pierre Vogt
Important clinical trials and therapeutic advances in the field of cardiology have been presented in 2014. New evidences on the management of acute myocardial infarction and the duration of dual antiplatelet therapy after coronary stent implantation have been published. A new class of therapeutic agents seems to offer promising perspectives for patients with heart failure and reduced ejection fraction. The new generation of subcutaneous or MRI-compatible implantable defibrillators is a major technological breakthrough...
January 14, 2015: Revue Médicale Suisse
Bryce D Beutler, Philip R Cohen
BACKGROUND: Reticular telangiectatic erythema is a benign cutaneous reaction that may occur in patients who have received a subcutaneous implantable cardioverter-defibrillator. Reticular telangiectatic erythema is characterized by asymptomatic telangiectasias, blanchable erythematous patches, or both overlying and/or adjacent to the subcutaneous implantable cardioverter-defibrillator. PURPOSE: We describe a man who developed reticular telangiectatic erythema after receiving a subcutaneous implantable cardioverter-defibrillator and review the salient features of this condition...
January 2015: Dermatology Practical & Conceptual
Lucie Ihnát Rudinská, Petr Hejna, Peter Ihnát, Margita Smatanová, Igor Dvořáček, Anatolij Truhlář
INTRODUCTION: Therapeutic procedures performed during cardiopulmonary resuscitation on patients in cardiac arrest or unconsciousness from any other cause can have serious adverse effects. Scale of injuries scale is very wide - from simple skin lacerations up to serious injuries which can even thwart possibility of successful resuscitation and cause death. MATERIALS AND METHODS: Comprehensive review of current literature aimed at injuries associated with cardiopulmonary resuscitation...
July 2014: Soudní Lékarství
Elia De Maria, Alina Olaru, Stefano Cappelli
The traditional transvenous defibrillator has been one of the greatest advancement in Cardiology in the last 30 years and has demonstrated to reduce arrhythmic and total mortality in selected patients. However the traditional defibrillator can have a high price to pay in terms of complications, the "weakest link" being the transvenous/endocardial leads. The entirely subcutaneous defibrillator (S-ICD) has recently entered into the clinical scenario and represents a valid alternative to the transvenous device...
2015: Current Cardiology Reviews
G Carrault, P Mabo
OBJECTIVES: The goal of this paper is to review some important issues occurring during the past year in Implantable devices. METHODS: First cardiac implantable device was proposed to maintain an adequate heart rate, either because the heart's natural pacemaker is not fast enough, or there is a block in the heart's electrical conduction system. During the last forty years, pacemakers have evolved considerably and become programmable and allow to configure specific patient optimum pacing modes...
August 15, 2014: Yearbook of Medical Informatics
Sally Aziz, Angel R Leon, Mikhael F El-Chami
The recently commercially available subcutaneous implantable cardioverter-defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrillation and tachycardia. The S-ICD offers the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks and shortcomings. However, its major disadvantage is its inability to provide bradycardia rate support and antitachycardia pacing to terminate ventricular tachycardia...
April 22, 2014: Journal of the American College of Cardiology
Arjun Majithia, N A Mark Estes, Jonathan Weinstock
Randomized clinical trials support the use of implantable defibrillators for mortality reduction in specific populations at high risk for sudden cardiac death. Conventional transvenous defibrillator systems are limited by implantation-associated complications, infection, and lead failure, which may lead to delivery of inappropriate shocks and diminish survival. The development of a fully subcutaneous defibrillator may represent a valuable addition to therapies targeted at sudden death prevention. The PubMed database was searched to identify all clinical reports of the subcutaneous defibrillator from 2000 to the present...
March 2014: American Journal of Medicine
Blandine Mondésert, Paul Khairy
PURPOSE OF REVIEW: Sudden cardiac death is a leading cause of mortality in patients with congenital heart disease (CHD), such that implantable cardioverter-defibrillators (ICDs) are a critical component of care. Objectives of this review are to highlight recent advances regarding ICDs in CHD, with a focus on clinical indications, technical issues and solutions, and patient outcomes. RECENT FINDING: Evolving ICD indications in CHD are primarily derived from observational research or extrapolations from the general adult literature...
January 2014: Current Opinion in Cardiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"